WPD Pharmaceuticals sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-09-01
Share capital
6,504,900.00 PLN
Activity description

WPD Pharmaceuticals has no active business operations and holds shares in its former Polish subsidiary, WPD Pharmaceuticals Sp. z o.o. The Polish company is a biotechnology research and development company focused on oncology, including medicinal products involving biological compounds and small molecules. WPD Pharmaceuticals lost control of the Polish company in November 2022.

Registered address
ul. Żwirki I Wigury 101, 02-089 Warszawa, Poland
Email
Electronic delivery address
AE:PL-73823-69657-FTTWF-21

Financials

Revenue history (in k)

Financial insight

  • The statement flags a going concern risk. Kapitał własny w bilansie spółki wykazuje wartość ujemną.

From the notes

Current income tax (CIT due)$0

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 130 days for 2022). 1 of 5 audited by a statutory auditor.

  • 2025filed
  • 202413/07/2025
  • 202312/07/2024
  • 202222/11/2023
  • 202103/10/2022
  • 202011/11/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 16%
City · Warszawa16,974 / 56,729
Top 30%
Voivodeship · Mazowieckie23,773 / 76,892
Top 31%
Country · Poland94,477 / 297,069
Top 32%

Results vs industry

Revenue
This companyUSD 919.18kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -741.31kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 1.51mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 539.90kMedianUSD 134.71kAverageUSD 3.04m

Websites

Public procurement

1 tender recorded as contractor, with a total value of $48,496.

SubjectAmount
Production of recombinant protein WPD101a together with analysis of the interaction of protein WPD101a with the IL-13Ra2 receptor
$48,496

Authorized Representatives

Mariusz Olejniczak age 52 – President of the Management Board

Manner of representation

In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
130,098$1,757,131.28100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2017-11-29.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Feb 21, 2022Call to creditors
Feb 21, 2022Call to creditors

Public aid

17 public aid cases recorded, with a total value of $22,342,028.

PurposeGross amount
Aid for research and development projects: industrial research
$536.5K
Aid for research and development projects: industrial research
$550.6K
Aid for research and development projects: experimental development
$191.7K

European Funds

ProjectEU co-financing
An innovative approach to the treatment of acute myeloid leukaemia (AML)
$5.3M
A new approach to glioma therapy addressing critical medical needs
$5.6M
Development of a new drug used to treat glioblastoma
$5.9M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
MAK Investments S.A.
Ekipa Holding S.A.
10X S.A.
KKV P.S.A.
Duda Holding sp. z o.o.
Picasso sp. z o.o.
Vicis New Investments S.A.
Grupa Coraz Lepsza Firma S.A.
JNT Group S.A.
Mediacap Investments sp. z o.o.

Change history

DateEvent
2024-02-19Share capital increase
2023-12-11Share capital increase
2023-10-14Share capital increase
2022-11-25Share capital increase
2022-06-13Share capital reduction

FAQ

Last updated: 2026-10-07